Rheumatoid Arthritis Therapeutics – Pipeline Assessment and Market Forecasts to2018ReportsnReports.com adds GlobalData Mar...
Reasons to buyThe report will enhance your decision-making capability. It will allow you to - Develop and design your in-...
3.11 Rheumatoid Arthritis Therapeutics Market Size (2005-2010) – Spain 263.12 Rheumatoid Arthritis Therapeutics Market For...
5.7.4 Iguratimod (T-614) 615.7.5 Secukinumab (AIN457) 625.7.6 Tofacitinib (CP-690550) 625.7.7 TuNEX 635.8 Key Takeaway 636...
List of TablesTable 1: Rheumatoid Arthritis Therapeutics Market, Global, Revenue ($bn), 2005 – 2010 15Table 2: Rheumatoid ...
Table   42:   GSK Rheumatoid Arthritis Pipeline 87Table   43:   GSK – Deals, Alliances and Partnerships 88Table   44:   Pf...
Figure 20: Rheumatoid Arthritis Therapeutics Market, Japan, Revenue ($m), 2005 – 201030Figure 21: Rheumatoid Arthritis The...
Upcoming SlideShare
Loading in …5
×

ReportsnReports – Rheumatoid Arthritis Therapeutics – Pipeline Assessment and Market Forecasts to 2018

497 views

Published on

GlobalData, the industry analysis specialist, has released its new report, “Rheumatoid Arthritis Therapeutics – Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global rheumatoid arthritis therapeutics market. The report identifies the key trends shaping and driving the global rheumatoid arthritis therapeutics market.

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
497
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

ReportsnReports – Rheumatoid Arthritis Therapeutics – Pipeline Assessment and Market Forecasts to 2018

  1. 1. Rheumatoid Arthritis Therapeutics – Pipeline Assessment and Market Forecasts to2018ReportsnReports.com adds GlobalData Market Research Report “Rheumatoid ArthritisTherapeutics – Pipeline Assessment and Market Forecasts to 2018 ’’ to its store.GlobalData, the industry analysis specialist, has released its new report, “RheumatoidArthritis Therapeutics – Pipeline Assessment and Market Forecasts to 2018”. The report isan essential source of information and analysis on the global rheumatoid arthritistherapeutics market. The report identifies the key trends shaping and driving theglobal rheumatoid arthritis therapeutics market.The report also provides insights on the prevalent competitive landscape and the emergingplayers expected to significantly alter the market positioning of the current market leaders.Most importantly, the report provides valuable insights on the pipeline products within theglobal rheumatoid arthritis therapeutics sector. This report is built using data andinformation sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.ScopeThe report provides information on the key drivers and challenges of the rheumatoidarthritis therapeutics market. Its scope includes - Annualized revenue data from seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) in the rheumatoid arthritis therapeutics market from 2005 to 2010, and forecasts for eight years to 2018. Pipeline analysis data, providing analysis split across the different phases, mechanisms of action being developed and emerging trends in the pipeline. Pipeline candidates fall under a variety of major therapeutic classes such as p38 kinase inhibitors, Janus Kinase Inhibitors (JAK), tyrosine kinase inhibitors, dihydrofolate reductase inhibitors, cyclooxygenase (COX) inhibitors, Dihydroorotate dehydrogenase (DHODH) inhibitors, interleukin inhibitors, tumor necrosis factor (TNF) inhibitors, chemotaxis inhibitors, Vascular Adhesion Protein-1 (VAP 1) inhibitors, granulocyte macrophage colony stimulating factor (GM-CSF) inhibitors, Toll-like receptors (TLRs) and anti-CD 20 monoclonal antibodies. Analysis of the current and future competition in the global rheumatoid arthritis therapeutics market. The key market players covered are AstraZeneca PLC, Eli Lilly and Company Eisai Co., Ltd GlaxoSmithKline plc, Pfizer Inc, Sanofi, Merck & Co., Inc., Novartis AG and Regeneron Pharmaceuticals, Inc. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the rheumatoid arthritis therapeutics market. Analysis of key recent licensing and partnership agreements in the rheumatoid arthritis therapeutics market.
  2. 2. Reasons to buyThe report will enhance your decision-making capability. It will allow you to - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines. Develop business strategies by understanding the trends shaping and driving the global rheumatoid arthritis therapeutics market. Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global rheumatoid arthritis therapeutics market in future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidations, investments and strategic partnerships. What’s the next big thing in the global rheumatoid arthritis therapeutics market landscape? – Identify, understand and capitalize.Table of contents1 Table of contents 31.1 List of Tables 51.2 List of Figures 62 Rheumatoid Arthritis Therapeutics Market – Introduction 72.1 Disease Overview 72.1.1 Classification and Diagnosis Criteria for Rheumatoid Arthritis 82.2 Epidemiology 82.3 Etiology 92.4 Sign and Symptoms 92.5 Diagnosis 102.5.1 Blood Tests 102.5.2 X-rays Testing 102.6 Pathophysiology 112.7 Treatment and Management Pattern 122.8 GlobalData Pipeline Report Guidance 133 Rheumatoid Arthritis Therapeutics – Market Characterization 143.1 Rheumatoid Arthritis Therapeutics Market Size (2005-2010) – Global 143.2 Rheumatoid Arthritis Therapeutics Market Forecast (2010-2018) – Global 163.3 Rheumatoid Arthritis Therapeutics Market Size (2005-2010) – The US 183.4 Rheumatoid Arthritis Therapeutics Market Forecast (2010-2018) – The US 193.5 Rheumatoid Arthritis Therapeutics Market Size (2005-2010) – France 203.6 Rheumatoid Arthritis Therapeutics Market Forecast (2010-2018) – France 213.7 Rheumatoid Arthritis Therapeutics Market Size (2005-2010) – Germany 223.8 Rheumatoid Arthritis Therapeutics Market Forecast (2010-2018) – Germany 233.9 Rheumatoid Arthritis Therapeutics Market Size (2005-2010) – Italy 243.10 Rheumatoid Arthritis Therapeutics Market Forecast (2010-2018) – Italy 25
  3. 3. 3.11 Rheumatoid Arthritis Therapeutics Market Size (2005-2010) – Spain 263.12 Rheumatoid Arthritis Therapeutics Market Forecast (2010-2018) – Spain 273.13 Rheumatoid Arthritis Therapeutics Market Size (2005-2010) – The UK 283.14 Rheumatoid Arthritis Therapeutics Market Forecast (2010-2018) – The UK 293.15 Rheumatoid Arthritis Therapeutics Market Size (2005-2010) – Japan 303.16 Rheumatoid Arthritis Therapeutics Market Forecast (2010-2018) – Japan 313.17 Drivers and Barriers for the Rheumatoid Arthritis Therapeutics Market 323.17.1 Drivers for Rheumatoid Arthritis Therapeutics Market 323.17.2 Barriers for Rheumatoid Arthritis Therapeutics Market 323.18 Opportunity and Unmet Need 333.19 Key Takeaway 344 Rheumatoid Arthritis Therapeutics Market – Competitive Assessment 354.1 Overview 354.1.1 Strategic Competitor Assessment 354.2 Product Profile for the Major Marketed Products in the Rheumatoid Arthritis Market 364.2.1 Actemra/RoActemra (tocilizumab) 364.2.2 Arcoxia (etirocoxib) 374.2.3 Celebrex (celecoxib) 384.2.4 Cimzia (certolizumab pegol) 394.2.5 Duexis (ibuprofen; famotidine) 404.2.6 Enbrel (etanercept) 404.2.7 Humira (adalimumab) 414.2.8 Lodotra / NP01 424.2.9 Orencia (Abatacept) 434.2.10 Remicade (infliximab) 444.2.11 Rituxan (rituximab) 454.2.12 Simponi (Golimumab) 454.3 Key Takeaway 465 Rheumatoid Arthritis Therapeutics – Pipeline Assessment 475.1 Overview 475.2 Strategic Pipeline Assessment 475.2.1 Technology Trends Analytic Framework 475.3 Rheumatoid Arthritis Therapeutics Pipeline – Pipeline by Phases of Development 485.3.1 Rheumatoid Arthritis Therapeutics – Phase III Pipeline 485.3.2 Rheumatoid Arthritis Therapeutics – Phase II/III Pipeline 485.3.3 Rheumatoid Arthritis Therapeutics – Phase II Pipeline 495.3.4 Rheumatoid Arthritis Therapeutics – Phase I/II Pipeline 515.3.5 Rheumatoid Arthritis Therapeutics – Phase I Pipeline 515.3.6 Rheumatoid Arthritis Therapeutics – Pre-clinical Pipeline 525.3.7 Rheumatoid Arthritis Therapeutics – Discovery Pipeline 545.4 Rheumatoid Arthritis Therapeutics – Pipeline by Mechanism of Action 555.5 Technology Trends Analytic Framework 575.6 Rheumatoid Arthritis Therapeutics – Promising Drugs Under Clinical Development 595.7 Promising Drugs Under Clinical Development 605.7.1 Anti-BAFF Monoclonal Antibody (LY2127399) 605.7.2 Arzerra (HuMax-CD20/ofatumumab) 605.7.3 Fostamatinib (R788) 61
  4. 4. 5.7.4 Iguratimod (T-614) 615.7.5 Secukinumab (AIN457) 625.7.6 Tofacitinib (CP-690550) 625.7.7 TuNEX 635.8 Key Takeaway 636 Rheumatoid Arthritis Therapeutics – Clinical Trials Mapping 646.1 Clinical Trials by Country (US, EU5 and Japan) 646.2 Clinical Trials by Phase 656.3 Clinical Trials by Trial Status 666.4 Overall Sponsors 676.5 Prominent Sponsor 686.6 Top Companies Participating in Rheumatoid Arthritis Therapeutics Clinical Trials 697 Rheumatoid Arthritis Therapeutics – Strategic Assessment 707.1 Key Events Impacting the Future Market 707.2 Rheumatoid Arthritis Market – Implications for Future Market Competition 718 Rheumatoid Arthritis Therapeutics – Future Players 728.1 Introduction 728.2 Company Profiles 728.2.1 AstraZeneca PLC 728.2.2 Eli Lilly and Company 788.2.3 Eisai Co., Ltd 828.2.4 GlaxoSmithKline plc 868.2.5 Pfizer, Inc. 918.2.6 Sanofi 968.2.7 Merck & Co. Inc. 1028.2.8 Novartis AG 1078.2.9 Regeneron Pharmaceuticals, Inc. 1118.2.10 Other Companies in the Rheumatoid Arthritis Therapeutics Market 1149 Rheumatoid Arthritis Therapeutics – Licensing and Partnership Deals 11710 Rheumatoid Arthritis Therapeutics – Appendix 12510.1 Market Definitions 12510.2 Abbreviations 12510.3 Methodology 12610.3.1 Coverage 12610.3.2 Secondary Research 12710.3.3 Forecasting 12710.3.4 Primary Research 13010.3.5 Expert Panel Validation 13010.4 Contact Us 13010.5 Disclaimer 13010.6 Bibliography 131
  5. 5. List of TablesTable 1: Rheumatoid Arthritis Therapeutics Market, Global, Revenue ($bn), 2005 – 2010 15Table 2: Rheumatoid Arthritis Therapeutics Market, Global, Revenue ($bn), 2010 – 2018 17Table 3: Rheumatoid Arthritis Therapeutics Market, The US, Revenue ($bn), 2005 – 2010 18Table 4: Rheumatoid Arthritis Therapeutics Market, The US, Revenue ($bn), 2010 – 2018 19Table 5: Rheumatoid Arthritis Therapeutics Market, France, Revenue ($m), 2005 – 2010 20Table 6: Rheumatoid Arthritis Therapeutics Market, France, Forecast ($m), 2010 – 2018 21Table 7: Rheumatoid Arthritis Therapeutics Market, Germany, Revenue ($m), 2005 – 201022Table 8: Rheumatoid Arthritis Therapeutics Market, Germany, Revenue ($m), 2010 – 201823Table 9: Rheumatoid Arthritis Therapeutics Market, Italy, Revenue ($m), 2005 – 2010 24Table 10: Rheumatoid Arthritis Therapeutics Market, Italy, Forecast ($m), 2010 – 2018 25Table 11: Rheumatoid Arthritis Therapeutics Market, Spain, Revenue ($m), 2005 – 2010 26Table 12: Rheumatoid Arthritis Therapeutics Market, Spain, Revenue ($m), 2010 – 2018 27Table 13: Rheumatoid Arthritis Therapeutics Market, The UK, Revenue ($m), 2005 – 201028Table 14: Rheumatoid Arthritis Therapeutics Market, The UK, Forecast ($m), 2010 – 201829Table 15: Rheumatoid Arthritis Therapeutics Market, Japan, Revenue ($m), 2005 – 2010 30Table 16: Rheumatoid Arthritis Therapeutics Market, Japan, Forecast ($m), 2010 – 2018 31Table 17: Rheumatoid Arthritis Therapeutics – Phase III Pipeline, 2011 48Table 18: Rheumatoid Arthritis Therapeutics – Phase II/III Pipeline, 2011 48Table 19: Rheumatoid Arthritis Therapeutics – Phase II Pipeline, 2011 49Table 20: Rheumatoid Arthritis Therapeutics – Phase I/II Pipeline, 2011 51Table 21: Rheumatoid Arthritis Therapeutics – Phase I Pipeline, 2011 51Table 22: Rheumatoid Arthritis Therapeutics – Pre-clinical Pipeline, 2011 52Table 23: Rheumatoid Arthritis Therapeutics – Discovery Pipeline, 2011 54Table 24: Rheumatoid Arthritis – Mechanisms of Action That Constitute Others in the AbovePie Chart 56Table 25: Rheumatoid Arthritis Therapeuics- Promising Drugs Under Clinical Development59Table 26: Rheumatoid Arthritis Therapeutics – Clinical Trials by Country, 2011 64Table 27: Rheumatoid Arthritis Therapeutics – Clinical Trials by Phase, 2011 65Table 28: Rheumatoid Arthritis Therapeutics – Clinical Trials by Status, 2011 66Table 29: Rheumatoid Arthritis – Overall Sponsors 67Table 30: Rheumatoid Arthritis Therapeutics – Prominent Sponsors, 2011 68Table 31: Rheumatoid Arthritis Therapeutics – Top Companies Participating in TherapeuticsClinical Trials, 2011 69Table 32: AstraZeneca’s Respiratory and Inflammation Pipeline 74Table 33: AstraZeneca’s Rheumatoid Arthritis Pipeline 74Table 34: AstraZeneca – Deals, Alliances and Partnerships 75Table 35: Eli Lilly and Company, Immunology Pipeline, 2011 79Table 36: Eli Lilly and Company, Rheumatoid Arthritis, Pipeline 79Table 37: Eli Lilly and Company – Deals, Alliances and Partnerships 79Table 38: Eisai Co., Ltd, Vascular and Immunological Reaction Pipeline 83Table 39: Eisai Co., Ltd, Rheumatoid Arthritis Pipeline 84Table 40: Eisai Co. Ltd – Deals, Alliances and Partnerships 84Table 41: GSK Immunoinflammatory Pipeline 87
  6. 6. Table 42: GSK Rheumatoid Arthritis Pipeline 87Table 43: GSK – Deals, Alliances and Partnerships 88Table 44: Pfizer Inflammation and Immunology Pipeline 93Table 45: Pfizer Rheumatoid Arthritis Pipeline 93Table 46: Pfizer – Deals Alliances and Partnership 94Table 47: Sanofi Internal Medicine Pipeline 98Table 48: Sanofi Rheumatoid Arthritis Pipeline 98Table 49: Sanofi – Deals Alliances and Partnership 99Table 50: Merck & Co. Immunology and Inflammatory Pipeline 104Table 51: Merck & Co. Rheumatoid Arthritis Pipeline 104Table 52: Merck & Co., Inc. – Deals Alliances and Partnership 104Table 53: Novartis AG, Inflammation and Immunology Pipeline, 2011 108Table 54: Novartis AG, Rheumatoid Arthritis Pipeline, 2011 108Table 55: Novartis AG – Deals, Alliances and Partnerships 109Table 56: Regeneron Pharmaceuticals, Inc, Immunology and Inflammatory Pipeline 112Table 57: Regeneron Pharmaceuticals, Inc, Rheumatoid Arthritis Pipeline 112Table 58: Regeneron Pharmaceuticals, Inc, Deals Alliances and Partnership 112Table 59: Rheumatoid Arthritis Therapeutics Market – Future Players 114Table 60: Rheumatoid Arthritis Therapeutics: Licensing and Partnership Deals 117List of FiguresFigure 1: Rheumatoid Arthritis – Stages or Phases 7Figure 2: Rheumatoid Arthritis – Conventional and New Classification Criteria 8Figure 3: Rheumatoid Arthritis – Pathophysiology 11Figure 4: Rheumatoid Arthritis Management – Algorithm Based on the EULARRecommendation 12Figure 5: Rheumatoid Arthritis Therapeutics Market, Global, Revenue ($bn), 2005 – 2010 14Figure 6: Rheumatoid Arthritis Therapeutics Market Share ($m, %), 2010 15Figure 7: Rheumatoid Arthritis Therapeutics Market Share ($m, %), 2018 17Figure 8: Rheumatoid Arthritis Therapeutics Market, The US, Revenue ($bn), 2005 – 201018Figure 9: Rheumatoid Arthritis Therapeutics Market, The US, Revenue ($bn), 2010 – 201819Figure 10: Rheumatoid Arthritis Therapeutics Market, France, Revenue ($m), 2005 – 201020Figure 11: Rheumatoid Arthritis Therapeutics Market, France, Forecast ($m), 2010 – 201821Figure 12: Rheumatoid Arthritis Therapeutics Market, Germany, Revenue ($m), 2005 –2010 22Figure 13: Rheumatoid Arthritis Therapeutics Market, Germany, Forecast ($m), 2010 –2018 23Figure 14: Rheumatoid Arthritis Therapeutics Market, Italy, Revenue ($m), 2005 – 2010 24Figure 15: Rheumatoid Arthritis Therapeutics Market, Italy, Forecast ($m), 2010 – 2018 25Figure 16: Rheumatoid Arthritis Therapeutics Market, Spain, Revenue ($m), 2005 – 2010 26Figure 17: Rheumatoid Arthritis Therapeutics Market, Spain, Revenue ($m), 2010 – 2018 27Figure 18: Rheumatoid Arthritis Therapeutics Market, The UK, Revenue ($m), 2005 – 201028Figure 19: Rheumatoid Arthritis Therapeutics Market, The UK, Forecast ($m), 2010 – 201829
  7. 7. Figure 20: Rheumatoid Arthritis Therapeutics Market, Japan, Revenue ($m), 2005 – 201030Figure 21: Rheumatoid Arthritis Therapeutics Market, Japan, Forecast ($m), 2010 – 2018 31Figure 22: Unmet Need in the Rheumatoid Arthritis Therapeutics Market, 2011 34Figure 23: Strategic Competitor Assessment of the Major Marketed Products for RheumatoidArthritis, 2010 36Figure 24: Rheumatoid Arthritis Therapeutics – Pipeline by Phase of Development, 2011 48Figure 25: Rheumatoid Arthritis Therapeutics – Pipeline by Mechanism of Action, 2011 55Figure 26: Rheumatoid Arthritis Therapeutics – Technology Trends Analytics Framework,2011 57Figure 27: Rheumatoid Arthritis Therapeutics – Technology Trends Analytics Framework –Description, 2011 58Figure 28: Rheumatoid Arthritis Therapeutics – Clinical Trials by Country, 2011 64Figure 29: Rheumatoid Arthritis Therapeutics – Clinical Trials by Phase, 2011 65Figure 30: Rheumatoid Arthritis Therapeutics – Clinical Trials by Status, 2011 66Figure 31: Rheumatoid Arthritis Therapeutics – Overall Sponsors, 2011 67Figure 32: Rheumatoid Arthritis Therapeutics – Prominent Sponsors, 2011 68Figure 33: Rheumatoid Arthritis Therapeutics – Top Companies Participating in TherapeuticsClinical Trials, 2011 69Figure 34: Rheumatoid Arthritis Therapeutics Market, Drivers and Restraints 2011 70Figure 35: Implications for Future Market Competition in Rheumatoid Arthritis, 2010 71Figure 36: Rheumatoid Arthritis Therapeutics – Pipeline by Company, 2011 72Figure 37: GlobalData Market Forecasting Model 129Latest Market Research Reports: Luxembourg Power Market Outlook to 2030 – Business Propensity Indicator ( BPI ) Market Trends Regulation and Competitive LandscapeAtopic Dermatitis Therapeutics – Pipeline Assessment and Market Forecasts to 2018 Cell Culture: The World Market for Media, Sera and Reagents, 3rd. Edition Fats and Salad/Cooking Oils in the U.S.: Butter, Margarine, Olive Oil, and Beyond Cell Culture: The World Market for Media, Sera and Reagents, 3rd. EditionAbout Us:ReportsnReports is an online library of over 75,000 market research reports and in-depthmarket research studies & analysis of over 5000 micro markets. We provide 24/7 online andoffline support to our customers. Get in touch with us for your needs of market researchreports.Follow us on Twitter: http://twitter.com/marketsreportsOur Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689Contact:Mr. Priyank7557 Rambler road,Suite 727, Dallas, TX 75231Tel: + 1 888 391 5441E-mail: sales@reportsandreports.comhttp://www.reportsnreports.comVisit Our Blog: Market Research Reports

×